March #194 : Treatment: Long-Acting ARVs for Low Adherers - by Benjamin Ryan

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents
 

Features

Empowering Entrepreneurs

Building Better Barriers

From the Editor

Justify My Love

Feedback

Letters-March 2014

The POZ Q+A

Southern Star

POZ Planet

Renewed Hope For Organ Transplants

Stigma Index Launches in United States

Say What? Greek Edition

POZ Stories: Blane Oborny

About That $615,000 Banksy?

R.I.P. Nelson Mandela

Fight Club

Wonder Women

Get Real: Focus on Female HIV Prevention

Voices

Tables Turned

Care and Treatment

HIV, Not ARVs, Linked to Hardened Arteries

Early Treatment Is Likely Heart Healthy

New Care Guidelines: Focus Beyond HIV

Vaginal Ring Prevents HIV and Pregnancy

A Ballooning Reservoir

Research Notes

Prevention: Breast Milk Protein May Protect Babies

Treatment: Long-Acting ARVs for Low Adherers

Cure: Baby in Remission 18 Months Off ARVs

Concerns: Tests Miss Milder Mental Impairment

POZ Heroes

Beyond the Boundary

   
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


email print

March 2014

Treatment: Long-Acting ARVs for Low Adherers

by Benjamin Ryan

The current crop of long-acting antiretrovirals (ARVs) in development, which hope to require only monthly or quarterly dosing, could increase the life spans of people with HIV, especially those with low adherence to daily regimens. Using mathematical models, researchers projected that, on average, long-acting ARVs would increase life expectancy by 0.5 to 0.6 years when compared with standard ARVs. For those with low adherence to standard ARVs, however, the benefit of switching to long-acting drugs would be an extra two to three years of life expectancy. The models also suggested that long-acting treatment would be cost-effective for those who have a history of poor adherence and who fail multiple regimens. Giving these therapies to those with lower adherence would increase its relative cost-effectiveness.

Search: ARVs, life span, adherence

Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Poll
Have you ever been diagnosed with diabetes or pre-diabetes?
Yes
No

Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.